Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to test the hypothesis that atomoxetine given at a dose of 1.2 mg/kg/day (once daily) for 12 weeks reduces symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) versus baseline in outpatients aged 13 through 17 years with a diagnosis of ADHD and comorbid cannabis abuse. ADHD symptoms are measured by ADHD Rating Scale-IV-Parent Version:investigator scored (ADHD-RS).
Critère d'inclusion
- Attention Deficit Hyperactivity Disorder